Answer to Question 1
Answer: C
Hydroxychloroquine (Plaquenil) is an antimalarial drug used in SLE to reduce the frequency of acute episodes of SLE. The primary concern with Plaquenil is retinal toxicity and possible irreversible blindness. Cushingoid effects are a concern with corticosteroid therapy. Pulmonary fibrosis is a potential adverse effect of cyclophosphamide, not Plaquenil. Renal toxicity is not the primary concern with Plaquenil.
Answer to Question 2
Answer: A, B, E
When teaching a client with SLE who is receiving immunosuppressant therapy, the nurse will tell the client to avoiding large crowds and situations that increase exposure to infection; to report difficulty breathing or a cough; and to maintain adequate oral hydration. The client should report a fever if it develops, and aspirin should not be used, as this may increase the risk for bleeding. Women may have an absence of menstruation, not heavy bleeding, during therapy.